OTCMKTS:VIVXF Avivagen (VIVXF) Stock Price, News & Analysis → This consistently signaled gains of 453%... 610%... and even 1036%... (From Insiders Exposed) (Ad) Free VIVXF Stock Alerts $0.0012 0.00 (0.00%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$0.0012▼$0.001250-Day Range N/A52-Week Range$0.0004▼$0.0149VolumeN/AAverage Volume5 shsMarket Capitalization$93,228.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsShort InterestStock AnalysisChartEarningsShort Interest Get Avivagen alerts: Email Address Ad WealthPressBuy Friday. Sell Monday. A 35 year old man from central Florida has stumbled on one of the best strategies we’ve seen in a long time. For the last 30 months his “Friday to Monday” trading strategy has maintained a 71% win rate on more than 350 trades. That includes multiple big time winners like 82% from Adobe… 77% from Palo Alto… But also a barrage of smaller winners like 20% from AMC… Each of which were opened on a Friday afternoon and closed the very next Monday morning. As you’ll see in his brand new video, this strange strategy has given him the ability to capture big time market moves over the weekend.Check it out, simply follow this link here. About Avivagen Stock (OTCMKTS:VIVXF)Avivagen Inc. focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. The company offers OxC-beta Livestock, a premix for inclusion in livestock feeds; Vivamune health chews for dogs; Dr. Tobias dog chews; and Dr. Tobias Beta blend for the human immune system. It serves in Canada, Mexico, Brazil, the Philippines, Taiwan, and Thailand. Avivagen Inc. was incorporated in 2005 and is headquartered in Ottawa, Canada.Read More VIVXF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VIVXF Stock News HeadlinesApril 27, 2024 | seekingalpha.comCYTO:CA Cytophage Technologies Ltd.March 16, 2023 | businesswire.comAvivagen Inc. Announces Results for the First Quarter Ending January 31, 2023May 30, 2022 | financialpost.comAvivagen Signs New Distribution Partner in Vietnam to Support Southeast Asian GrowthMarch 22, 2022 | financialpost.comAvivagen to Attend CEM Sponsored Alpha North ConferenceSee More Headlines Receive VIVXF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avivagen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/18/2024Next Earnings (Estimated)6/04/2024Fiscal Year End10/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private households Sub-IndustryN/A Current SymbolOTCMKTS:VIVXF CUSIPN/A CIKN/A Webwww.avivagen.com Phone613-702-2908FaxN/AEmployees13Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$730,000.00 Price / Sales0.13 Cash FlowN/A Price / Cash FlowN/A Book Value($0.06) per share Price / Book-0.02Miscellaneous Outstanding Shares77,690,000Free Float76,063,000Market Cap$93,228.00 OptionableNot Optionable Beta-0.30 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. G. F. Kym Anthony (Age 68)CEO & Vice Chairman Comp: $265.84kDr. Graham Burton Ph.D.Co-Founder, Chief Scientific Officer & DirectorMr. Ira LevyInterim Chief Financial OfficerDr. James Nickerson Ph.D.President and Executive VP of Business Development & Product InnovationMr. Drew BasekDirector of Investor RelationsMs. Tracy Gillett BVSCDirector of Companion Animal & Marketing ManagerMore ExecutivesKey CompetitorsReNeuron GroupOTCMKTS:RNUGFAdhera TherapeuticsOTCMKTS:ATRXCalithera BiosciencesNASDAQ:CALAScopus BioPharmaNASDAQ:SCPSQ BioMedOTCMKTS:QBIOView All Competitors VIVXF Stock Analysis - Frequently Asked Questions How have VIVXF shares performed in 2024? Avivagen's stock was trading at $0.0006 at the start of the year. Since then, VIVXF shares have increased by 100.0% and is now trading at $0.0012. View the best growth stocks for 2024 here. Are investors shorting Avivagen? Avivagen saw a decrease in short interest during the month of April. As of April 15th, there was short interest totaling 14,300 shares, a decrease of 41.2% from the March 31st total of 24,300 shares. Based on an average trading volume of 2,000 shares, the days-to-cover ratio is presently 7.2 days. View Avivagen's Short Interest. When is Avivagen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 4th 2024. View our VIVXF earnings forecast. How do I buy shares of Avivagen? Shares of VIVXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:VIVXF) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersObama’s Forever Term [exposed]Porter & CompanyShocking $16T Elon Musk Crypto LeakCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe Presidential candidate you should REALLY be worried aboutStansberry ResearchForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressMost important medical advance in 100 yearsThe Oxford ClubMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders Alliance Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avivagen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.